HOME   AGENDA   SPEAKERS   PROGRAMS   INVESTORS   CAREER   PAST SUMMITS   REGISTRATION  
2019 PRE-JPM
CTIC HEALTHCARE INVESTMENT SUMMIT
JANUARY 6, 2019
SAN FRANCISCO, CA
InterContinental San Francisco
888 Howard St, San Francisco, CA 94103

SHARPENING YOUR FOCUS
Implementation of The Committee on Foreign Investment in the United States (CFIUS) on November 10, 2018, has made cross-border fundraising and partnering efforts more complicated. Precision, focus, and clarity are critical at such times when funding sources may be decreasing and the period for fundraising may be increasing.
CTIC Capital 2019 is proud to offer you strategies and connections to counter these difficulties.
At our January 2019 Summit Investors to Company CEO Ratio is targeted to be 2:1, with estimated 150-200 total investors attending
All of our speakers are Partners or Managing Directors of well-known firms
90 percent of the most active investors in cross-border investments in 2018 will be speakers or attendees of our summit
One-on-One partnering system will assist in submitting inquiries for meetings with investors and companies during the summit
New to 2019 we will also have many partners of Asian funds attending our summit
 

PARTIAL CONFIRMED SPEAKERS
RUILIN SONG (KEYNOTE)
Executive President
China Pharmaceutical Innovation and Research
Development Association (PhIRDA)
 
FENG DENG (KEYNOTE)
Founding Managing Director
Northern Light Venture Capital
 
JOSH BERLIN
Executive Director & Editor of New
VenturesBioCentury Inc
 
KEVIN CHEN
Managing Partner
Biotrack Capital
 
KETING CHU
Venture Partner
LYFE Capital
 
TED DRISCOLL
Managing Director
DigitalDX Ventures
 
TAO FU
President and COO
Zai Lab
 
JOSHUA GRUENSPECHT
Of Counsel, Regulatory and
Compliance
 
FENG HAN
Managing Director
Fosun Group
 
BOSUN HAU
Managing Director & Partner
Sailing Capital
 
MICHAEL FU
Managing Director and Head of Everbright Healthcare Fund
China Everbright Holding
 
XIAOFANG HU
CD Capital
Managing Director
 
JAMES HUANG
Managing Partner, KPCB China
Managing Partner, Panacea Venture
 
JAMES JENSEN
Partner
Corporate
 
ALEXIS JI
Partner
Illumina Ventures
 
NISA LEUNG
Managing Partner
Qiming Venture Partners
 
BIN LI
Partner and Managing Director
Ally Bridge Group
 
JENNY LIU
Director, Corporate Finance
Haitong International Capital Limited
 
CHERRY LU
Founding & Managing Partner, Redhill Capital
Venture Partner, Sequoia Capital China
 
HONGBO LU
Partner
Lilly Asia Ventures
 
TIMOTHY K. LU
Associate Professor of Biological
Engineering and Electrical Engineering
and Computer Science at MIT
 
XIAOBO LU
Partner
Sequoia Capital China
 
HAI MI
Founding Managing Partner
Panacea Ventures
 
ANDREW NG
Managing Director, Head of
Healthcare, Private Equity
VMS Investment Group
 
NICK PLIAM
Partner
Decheng Capital
 
VICTOR SHI
Chairman, BayHelix
Managing Partner, Serica Partners
 
BARRY TAYLOR
Partner
Corporate
 
JONATHAN WANG
Partner
OrbiMed
 
KAREN WONG
Partner
Intellectual Property
 
WEI WU
Healthcare Investment Director
BOE Ventures
 
VINCENT XIANG
Managing Director
Hillhouse Capital
 
KEVIN XIE
President of Fosun Healthcare Holdings
Chief Representative of Fosun US
 
STELLA XU
Managing Director
Quan Capital
 
GUO-LIANG YU
Venture Partner
OrbiMed
 
JIANBIN ZHANG
Partner
IDG Capital
 
LU ZHANG
Founder and Managing Partner
Fusion Fund
 
TONG ZHANG
Managing Director
C-Bridge Capital
 
JAMES ZHAO
Founding Partner
LYFE Capital
 
RICHARD ZHAO
Partner
Tasly International Capital
 
RUILIN ZHAO
Partner
CD Capital
 
PEI ZHOU
Partner
Pagoda Capital Partners
   
 

PARTIAL CONFIRMED INVESTMENT FIRMS
         
 

PROGRAMS
 
GENERAL ADMISSION
• 150-200 Asian healthcare investors
• Well known investors and speakers
• 2: 1 Investors to Company CEO ratio
 
Healthcare Company: $499*
Service Provider: $1,099*
REGISTRATION
*Current Pricing (Ends on 12/21/18)
   
  
• Schedule face-to-face meetings with the most relevant Asian Healthcare Investors
• Easy-to-use meeting scheduling platform
   
No Additional Fee. Included in General Admission
OPEN NOW
   
   
PRESENTING PACKAGE
• Limited spots to present to the most active Asian Investors at the Summit
• Format: 10 minutes presenting plus 5 minutes investors on-stage review and discussions
   
Presenting Fee: $5,000
APPLY
INVESTOR INTRODUCTION
• Targeted direct investors introductions
• Prepare funds and investors background information
• Facilitate face-to-face meetings during CTIC Investment Summit or JPM week*
   
Please ask for details
APPLY
*Depends on levels of selected package
 

AGENDA
MORNING SESSION
  07:30-09:00AM Breakfast / Networking
  09:00-09:15AM Welcoming Remark
    Yanhong Lin, Managing Partner, CTIC Capital
Victor Shi, BayHelix Chairmen; General Partner, Serica Partners
  09:15-09:45AM Keynote: The Chinese Pharmaceutical Industry: Innovation and Policy Reform
    Ruilin Song, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA)
  09:45-09:55AM Fireside Chat with President Song, PhIRDA
    Kevin Chen, Managing Partner, Biotrack Capital
  09:55-10:45AM Panel Discussion I: Trends in Therapeutic Investments and Partnerships
    Keting Chu, Venture Partner, LYFE Capital
Tao Fu, President and COO, Zai Lab
James Huang, Managing Partner, KPCB China; Managing Partner, Panacea Venture
Hongbo Lu, Partner, Lilly Asia Ventures
Timothy Lu, Associate Professor of Biological Engineering and Electrical Engineering and Computer Science, MIT
Vincent Xiang, Managing Director, Hillhouse Capital
  10:45-11:30AM Panel Discussion II: The Age of the Cross-Border Collaborations – Opportunities and Challenges
    Nisa Leung, Managing Partner, Qiming Venture Partners
Xiaobo Lu, Partner, Sequoia Capital China
Jonathan Wang, Partner, OrbiMed
Kevin Xie, President of Fosun Healthcare Holdings, Chief Representative of Fosun US
Jianbin Zhang, Partner, IDG Capital
James Zhao, Founding Partner, LYFE Capital
  11:30-01:00PM Lunch / Special Session Hosted by WSGR: CFIUS Reform - Navigating Its Impact on Healthcare Industry
    Joshua Gruenspecht, Of Counsel, Regulatory and Compliance, WSGR
James Jensen, Partner, Corporate, WSGR
Barry Taylor, Partner, Corporate, WSGR
Karen Wong, Partner, Intellectual Property, WSGR
AFTERNOON SESSION
  01:00-01:35PM Keynote: Challenges and Opportunities in the Healthcare Industry
    Feng Deng, Founding Managing Director, Northern Light Venture Capital
  01:35-02:50PM Company Presenting Session I - Hosted by Josh Berlin, Biocentury
    Bigfoot Biomedical / Michael Fu, Managing Director, China Everbright Holding
Genosco / Tong Zhang, Managing Director, C-Bridge Capital
HYCOR BioMedical / Bosun Hau, Managing Director and Partner, Sailing Capital
Mesoblast / Stella Xu, Managing Director, Quan Capital
NeuroRx / Hai Mi, Founding Managing Partner, Panacea Ventures
  02:50-03:35PM Panel Discussion III: Asian Exit Opportunities in Healthcare
    Jenny Liu, Director, Corporate Finance, Haitong International Capital Limited
Bin Li, Partner and Managing Director, Ally Bridge Group
Cherry Lu, Partner, Red Hill Capital
Andrew Ng, Managing Director, Head of Healthcare, Private Equity, VMS Investment Group
Nick Pliam, Partner, Decheng Capital
Richard Zhao, Partner, Tasly International Capital
  03:35-04:35PM Company Presenting Session II - Hosted by Josh Berlin, BioCentury
    Oncolmmune / Keting Chu, Venture Partner, LYFE Capital
Oxford BioTherapeutics / Wei Wu, Healthcare Investment Director, BOE Ventures
Sirnaomics / Pei Zhou, Partner, Pagoda Capital Partners
Travera / Xiaofang Hu, Managing Director, CD Capital
  04:35-05:20PM Panel Discussion IV : Investment Opportunities: In Vitro Diagnostics and Medical Devices
    Lu Zhang, Founder and Managing Partner, Fusion Fund
Ted Driscoll, Managing Director, DigitalDX Ventures
Feng Han, Managing Director, Fosun Group
Bosun Hau, Managing Director & Partner, Sailing Capital
Alexis Ji, Partner, Illumina Ventures
Ruilin Zhao, Partner, CD Capital
  05:20-05:30PM Closing Remarks and Raffle
    Guo-Liang Yu, Co-founder, CBT Pharmaceuticals; Venture Partner, OrbiMed
 

PAST SUMMITS

CTIC CAPITAL
     
 
CTIC Capital is a Silicon Valley based cross-border healthcare consulting firm. CTIC Capital helps enterprises in US and China in funding, M&A, and strategic partnership development by leveraging our Trans-Pacific network and local expertise. Our goal is to be the trusted advisor to companies for US-China cross-border investment and partnership opportunities.
  
     
 

CONTACT US
 
ning.feng@cticcapital.com
yanhong.lin@cticcapital.com